Cyclacel Pharma (CYCC) Misses Q2 EPS by 4c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/9/2026

1. HUM
2. SPCX
3. ALHC
4. T
5. PEP
6. CVS
7. UNH
8. ZETA
9. DAL
10. TMUS

Go back to Cyclacel Pharma (CYCC) Misses Q2 EPS by 4c

Cyclacel Pharmaceuticals Reports Second Quarter 2018 Financial Results

August 9, 2018 4:05 PM EDT

BERKELEY HEIGHTS, N.J., Aug. 09, 2018 (GLOBE NEWSWIRE) -- Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC, NASDAQ: CYCCP; "Cyclacel" or the "Company"), a biopharmaceutical company developing innovative medicines based on cancer biology, today reported financial results and business highlights for the second quarter 2018.  

The Company's net loss applicable to common shareholders for the three months ended June 30, 2018 was $1.9 million.  As of June 30, 2018, cash and cash equivalents totaled $19.8 million.

Phase 1 data presented for CYC065, our lead CDK inhibitor, at the recent American Association for Cancer Research Annual Meeting highlighted CYC065s potential for durable suppression of Mcl-1, a... More